Last updated: March 1, 2026
What is the Indication and Formulation?
NDC 68599-2301 corresponds to Ruzurgi (amifampridine) tablets, approved by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in patients 6 years and older. The drug is supplied in 15 mg tablets.
Market Overview
Patient Population
- Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder affecting approximately 3-4 cases per million annually in the U.S.
- Estimated prevalent cases of LEMS in the U.S. range from 1,500 to 2,000.
- Ruzurgi targets a niche patient segment, primarily pediatric and adult patients with diagnosed LEMS.
Competitive Landscape
- First-line treatment is symptomatic, primarily using 3,4-DAP (dextro-3,4-diaminopyridine), which is an unapproved generic.
- Ruzurgi is the only FDA-approved product for pediatric LEMS, providing a unique positioning.
Market Dynamics
- Prescriptions are driven by neurologists and neuromuscular specialists.
- Diagnosis rates are low, owing to the rarity of LEMS and underdiagnosis.
- The drug's limited indication scope constrains earnings potential but positions it as a potential "gold standard" in pediatric cases.
Price Analysis
Current Pricing
- List price per 15 mg Ruzurgi tablet averages around $600 to $650 (Wholesaler Acquisition Cost, WAC).
- Monthly treatment (assuming daily dosage of 4 tablets) costs approximately $73,000 to $80,000.
Reimbursement and Pricing Trends
- Insurance reimbursement aligns with WAC or Average Wholesale Price (AWP) plus negotiated discounts.
- The drug's orphan status limits competition but also constrains pricing pressure.
Price Comparisons
| Product |
Indication |
Price per Dose |
Notes |
| Ruzurgi |
LEMS (pediatric) |
~$600 |
15 mg tablet |
| Generic D-3,4-DAP |
LEMS (adult, unapproved) |
~$10 |
Off-label, formulary variability |
Note: Off-label use by compounding pharmacies can lower prices but lacks FDA approval standards.
Market Projections
Revenue Forecasts (Next 5 Years)
| Year |
Estimated U.S. Prescriptions |
Revenue (USD) |
Assumptions |
| 2023 |
100-150 |
$8-12 million |
Stabilized prescriptions, limited growth due to rarity |
| 2024 |
125-180 |
$10-14 million |
Slight growth, increased awareness |
| 2025 |
150-210 |
$12-17 million |
Market penetrationdeepens moderate |
| 2026 |
180-250 |
$14-20 million |
Potential label expansion for broader LEMS use |
| 2027 |
200-280 |
$16-23 million |
Market stabilization, pricing pressures minimal |
Projections assume slow but steady prescription increase driven by better diagnosis and awareness.
Key Factors Influencing Market Growth
- Label Expansion: Potential for approval for adult LEMS if clinical data supports safety/effectiveness.
- Increased Diagnoses: Enhanced recognition in neuromuscular disorders could increase prescriptions.
- Pricing Strategies: Negotiations with payers may influence net pricing.
Risks and Challenges
- Off-label use of generic D-3,4-DAP may limit Ruzurgi's market share.
- Manufacturing costs could influence wholesale prices and margins.
- Insurance coverage variability will affect patient access and revenue.
Summary
| Aspect |
Details |
| Current Price Range |
$600–$650 per 15 mg tablet |
| Annual Revenue Potential |
$8–23 million in the next five years, heavily dependent on prescriptions and approval expansions |
| Market Drivers |
Rarity of LEMS, pediatric indication, FDA approval status |
| Market Constraints |
Rare disease prevalence, competition from off-label generics |
Key Takeaways
- Ruzurgi fills a niche for pediatric LEMS with limited competition.
- Pricing remains high due to rare disease status and small patient populations.
- Market growth depends on diagnosis rates, clinical trials for label expansion, and payer coverage.
- New approvals or indications could significantly impact market size.
- Competition from off-label compounded D-3,4-DAP poses ongoing challenges.
FAQs
1. What factors influence Ruzurgi’s pricing strategy?
Pricing is driven by manufacturing costs, rarity-based reimbursement policies, and negotiations with payers, considering its orphan status and FDA approval for pediatric patients.
2. How does Ruzurgi compare to off-label D-3,4-DAP?
Ruzurgi offers FDA approval and consistent quality, whereas off-label D-3,4-DAP is cheaper but lacks standardized manufacturing and regulatory oversight.
3. What is the potential for market expansion?
Label extension to include adult LEMS could broaden the addressable population, potentially increasing prescriptions by up to 50-100%.
4. How is the disease prevalence impacting sales?
The low prevalence of LEMS limits the total market, constraining revenue but enabling premium pricing for approved therapy.
5. What are the main risks to long-term sales?
The entry of generic D-3,4-DAP, payer restrictions, or regulatory hurdles for label extension could diminish sales prospects.
Sources
- U.S. Food and Drug Administration. FDA Drug Approval Packages. (2022).
- Market Data Forecast. LEMS market analysis report. (2023).
- IQVIA. Prescriber and prescription trends. (2022).
- Manufacturer’s pricing disclosures. (2023).
- Orphan Drug Designations and Incentives. FDA website. (2023).
